Lipoprotein(a) levels and time to cardiovascular benefit with alirocumab in patients with recent acute coronary syndrome
Author(s)
Type
Journal Article
Abstract
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
Date Issued
2025-11-25
Date Acceptance
2025-08-19
Citation
JACC, 2025, 86 (21), pp.2071-2076
ISSN
0735-1097
Publisher
Elsevier BV
Start Page
2071
End Page
2076
Journal / Book Title
JACC
Volume
86
Issue
21
Copyright Statement
© 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creative commons.org/licenses/by-nc-nd/4.0/).
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/40892611
PII: S0735-1097(25)07551-5
Subjects
MACE
MALE
acute coronary syndromes
alirocumab
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2025-08-27